Collectively, a series of large, prospective randomised outcome trials has now shown that angiotensin receptor blockers (ARBs) are of clinical value in a broad spectrum of patients with symptomatic heart failure, regardless of background therapy and ventricular function. There is a clear benefit of ARBs in patients unable to tolerate an angiotensin-converting enzyme (ACE) inhibitor and this benefit is of a similar magnitude to that obtained with an ACE inhibitor (ACE-I). Both Val-HeFT and, particularly, CHARM-Added, also show that symptoms, morbidity and mortality are further reduced if an ARB is added to an ACE-I. This benefit is not only statistically significant but clinically important. CHARM-Preserved showed that candesartan can reduce hospital admission for heart failure in patients with preserved systolic function though more definitive outcome data are needed in this group.
Cowie MR, Mosterd A., Wood DA et al. The epidemiology of heart failure. Eur Heart J1997;18:208-25.
2.
McMurray JJ, Stewart S.Epidemiology, aetiology, and prognosis of heart failure. Heart2000;83:596-602.
3.
Petrie M., McMurray J.Changes in notions about heart failure. Lancet2001;358:432-4.
4.
The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med1987;316: 429-35.
5.
The SOLVD Investigators.Effect of enalparil on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med1991;325:293-302.
6.
Garg R., Yusuf S.Overview of randomized trials of angiotensin-converting enzyme inhibitors on the mortality and morbidity in patients with heart failure. JAMA1995;18:1450-5.
7.
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet1999;353:9-13.
8.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) [editorial]. Lancet1999; 53:2001-07.
9.
Packer M., Coats AJ, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure . N Engl J Med2001; 344:1651-8.
10.
Pitt B., Zannad F., Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators . N Engl J Med1999;341:709-17.
11.
The Digitalis Investigation Group.The effect of digoxin on mortality and morbidity in patients with heart failure . N Engl J Med1997;336:525-33.
12.
Stewart S., MacIntyre K., MacLeod MM et al. Trends in hospitalization for heart failure in Scotland, 1990-1996.An epidemic that has reached its peak?Eur Heart J2001;22:209-17.
13.
Hamroff G., Katz SD, Mancini D. et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation1999;99:990-2.
14.
McKelvie RS ,Yusuf S., Pericak D. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation1999 ;100:1056-64.
15.
McKelvie RS , Rouleau JL, White M. et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J2003;24:1727-34.
16.
Latini R., Masson S., Anand I. et al. Valsartan Heart Failure Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation2002;106:2454-8.
17.
Cohn JN,Anand IS, Latini R. et al. Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation2003;108:1306-09.
18.
Granger CB, Ertl G., Kuch J. et al. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am Heart J2000;139:609-17.
19.
Pitt B., Poole-Wilson PA, Segal R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet2000;355:1582-7.
20.
Cohn JN, Tognoni G.Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med2001; 45:1667-75.
21.
Swedberg K. , Pfeffer M., Granger C. et al. Candesartan in heart failure - assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Cardiac Fail1999;5:276-82.
22.
McMurray J. , Östergren J., Pfeffer M. et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme . Eur J Heart Fail2003;5:261-70.
23.
Granger CB, McMurray JJ, Yusuf S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet2003;362:772-6.
24.
McMurray JJ , Östergren J., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet2003;362:767-71.
25.
Yusuf S., Pfeffer MA, Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial . Lancet2003;362: 777-81.
26.
Pfeffer MA, Swedberg K., Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet2003; 362:759-66.
27.
Brenner BM, Cooper ME, de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med2001;345:861-9.
28.
Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes . N Engl J Med2001;345:851-60.
29.
Berl T., Hunsicker LG, Lewis JB et al. Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med2003;138:542-9.
30.
Dahlof B., Devereux RB, Kjeldsen SE et al. LIFE Study Group.Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study 359:995-1003. (LIFE): a randomised trial against atenolol . Lancet2002;
31.
Lithell H., Hansson L., Skoog I. et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens2003;21:875-86.
